7 Investor presentation First three months of 2023 International Operations diabete GLP-1 performance Reported Diabetes care sales and growth per IO geography DKK billion Insulin GLP-1 Growth at CER 20 12% 15 52% 10 5 -8% 0 IO Geographical regions 19% 57% -5% EMEA -7% 56% -22% China 17% 40% 4% RoW IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiw Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP- 1 class growth calculated as Dec Source: IQVIA MAT, Feb 2023 (Spot rate). Volume packs are converted into full-year patients based on WHO assumptions for averag
Download PDF file